BrighTNess Follow-Up Data Shed Light on TNBC Therapy BrighTNess Follow-Up Data Shed Light on TNBC Therapy

Patients with triple negative breast cancer had improved event-free survival when carboplatin (but not the PARP inhibitor veliparib) was added to standard neoadjuvant chemotherapy.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Related Links:

Lower (
Source: Journal of the American College of Surgeons - Category: Surgery Authors: Tags: Breast Source Type: research
We report on a 52-year-old woman with breast cancer admitted in our institution for onycholysis. Because of the stage and histology of breast cancer, neoadjuvant chemotherapy was initiated. The patient received 8 cycles of Taxotere and Adriamycin (AT), and she underwent a modified radical mastectomy. Three months later, the patient developed evidence of onycholysis, involving all the fingernails. We observed the following changes in nails of all the digits in both hands: onycholysis, dystrophy, oedema, and exudate. Nail scraping and purulent discharge were collected and cultured on Sabouraud medium. Physical features of th...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Triple Negative Breast Cancer (TNBC) Interventions:   Drug: Camrelizumab;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel Sponsor:   Aiping Shi Recruiting
Source: - Category: Research Source Type: clinical trials
Ann Surg Oncol. 2021 Oct 20. doi: 10.1245/s10434-021-10830-4. Online ahead of print.NO ABSTRACTPMID:34671883 | DOI:10.1245/s10434-021-10830-4
Source: Ann Oncol - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: Luminal B-like BCs with a Basal molecular subtype and/or a state of immune activation may respond to sequential anthracyclines and anti-PD-1. Our data generate hypotheses that, if validated, could guide immunotherapy development in this context.PMID:34667023 | DOI:10.1158/1078-0432.CCR-21-2260
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
In this study, we examined the roles of cytokines in both serum and exosomes as prognostic biomarkers for long-term outcomes in patients with breast cancer who undergo NAC. We isolated exosomes from the blood of 129 patients with early breast cancer who were receiving neoadjuvant chemotherapy between 2008 and 2011 at Samsung Medical Center. The levels of cytokines and growth factors in serum and exosomes were measured with ProcartaPlex immune-related panels. We investigated correlations between clinic-pathologic variables and patient survival, and Cox proportional hazards regression analysis was performed for prognostic ev...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conclusion: Molecular analysis and subtyping of TNBC may be relevant to identify patients with LAR subtype. These cancers seem to be less sensitive to conventional chemotherapy, and new treatment options, including androgen receptor-blocking agents and immune checkpoint inhibitors, have to be explored.Breast Care
Source: Breast Care - Category: Cancer & Oncology Source Type: research
J Reconstr Microsurg DOI: 10.1055/s-0041-1736319 Background Triple-negative (TN) and luminal A breast cancer molecular subtypes have divergent clinical and prognostic characteristics for breast cancer patients. Our study aims to compare the reconstructive choice of these two groups from the time they receive a tissue expander (TE) to the time they complete autologous or implant-based breast reconstruction. Methods A total of 255 patients who underwent delayed-immediate breast reconstruction with TE placement from 2013 to 2017 diagnosed with either TN (n = 73) or luminal A (n = 18...
Source: Journal of Reconstructive Microsurgery - Category: Surgery Authors: Tags: Original Article Source Type: research
In conclusion, cell proliferation, immune response, and NAC breast cancer response was associated with MELK expression.PMID:34659896 | PMC:PMC8493385
Source: Cell Research - Category: Cytology Authors: Source Type: research
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Hematology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy